Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists

References

• American Lung Association. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality. Chicago, IL: American Lung Association; 2013
   Google Scholar
• Tilert T, Dillon C, Paulose-Ram R, et al. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010. Respir Res 2013;14:103
   PubMed Web of Science ®Google Scholar
• Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveillance Summaries 2002;51(SS06):1-16
   Google Scholar
• Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2013
   Google Scholar
• Wacker ME, Hunger M, Karrasch S, et al. Health-related quality of life and chronic obstructive pulmonary disease in early stages – longitudinal results from the population-based KORA cohort in a working age population. BMC Pulm Med 2014;14:134-45
   PubMed Web of Science ®Google Scholar
• Janson C, Marks G, Buist S, et al. The Impact of COPD on health status: findings from the BOLD study. Eur Respir J 2013;42:1472-83
   PubMed Web of Science ®Google Scholar
• Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005;9:3-56
   Google Scholar
• DiBonaventura MD, Paulose-Ram R, Su J, et al. The impact of COPD on quality of life, productivity loss, and resource use among the elderly United States workforce. COPD 2012;9:46-57
   PubMedGoogle Scholar
• Garrido PC, de Miguel Diez J, Gutierrez JR, et al. The negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006;4:31
   PubMed Web of Science ®Google Scholar
• Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010;5:341-9
   PubMedGoogle Scholar
• Dalal AA, Liu F, Riedel AA. Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int J Chron Obstruct Pulmon Dis 2011;6:533-42
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013;5:235-45
   PubMedGoogle Scholar
• Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010;7:214-28
   PubMedGoogle Scholar
• Yu AP, Yang H, Wu EQ, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011;14:315-23
   PubMedGoogle Scholar
• Blanchette CM, Dalal AA, Mapel D. Changes in COPD demographics and costs over 20 years. J Med Econ 2012;15:1176-82
   PubMedGoogle Scholar
• Blanchette CM, Gross NJ, Altman P. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits 2014;7:98-106
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Updated 2015. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed March 30, 2015
   Google Scholar
• Meyer KC. COPD 2013: an update on treatment and newly approved medications for pharmacists. J Am Pharm Assoc (2003) 2013;53:e219-29
   PubMed Web of Science ®Google Scholar
• Bollu V, Ejzykowicz F, Rajagopalan K, et al. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ 2013;16:1082-8
   PubMedGoogle Scholar
• Bollu V, Ernst FR, Karafilidis J, et al. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis 2013;8:631-9
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133:1079-87
   PubMed Web of Science ®Google Scholar
• Wang J, Nie B, Xiong W, et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012;37:204-11
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8
   PubMed Web of Science ®Google Scholar
• Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2011;68:1221-32
   PubMed Web of Science ®Google Scholar
• Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD 2012;9:58-72
   PubMedGoogle Scholar
• Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50:1313-21; discussion 1321–2
   PubMedGoogle Scholar
• Handley D, Senanayake C, Dutczak W, et al. Biological actions of formoterol isomers. Pulm Pharmacol Ther 2001;15:135-45
   Web of Science ®Google Scholar
• Pahwa R, Soni V, Sharma PC, et al. Arformoterol tartrate: a review of pharmacology, analysis and clinical studies. Trop J Pharm Res 2010;9:595-603
   Web of Science ®Google Scholar
• Hanania NA, Donohue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD 2010;7:17-31
   PubMedGoogle Scholar
• Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29:261-78
   PubMed Web of Science ®Google Scholar
• Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respir Med 2008;102:173-88
   PubMed Web of Science ®Google Scholar
• Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med 2010;4:155-62
   PubMedGoogle Scholar
• Gross NJ, Donohue JF. Nebulized formoterol: a review of clinical efficacy and safety in COPD. Int J Chron Obstruct Pulmon Dis 2010;5:223-32
   PubMedGoogle Scholar
• Hanrahan JP, Hanania NA, Calhoun WJ, et al. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 2008;5:25-34
   PubMedGoogle Scholar
• Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis 2013;7:81-6
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS’ PharMetrics Plus™ Data Dictionary. http://tri.uams.edu/wp-content/uploads/2011/10/PMXPlusDataDictionaryAugust2013.dotx.pdf. Accessed March 30, 2015
   Google Scholar
• Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med 2015;30:51-9
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7
   PubMed Web of Science ®Google Scholar
• Roos LL, Stranc L, James RC, et al. Complications, comorbidities, and mortality: improving classification and prediction. Health Serv Res 1997;32:229-38; discussion 239–42
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Mullerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res 2013;14:79
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
   PubMed Web of Science ®Google Scholar
• Pasquale MK, Sun SX, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis 2012;7:757-64
   PubMed Web of Science ®Google Scholar
• AbuDagga A, Sun SX, Tan H, et al. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis 2013;8:175-85
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD—a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009;4:203-23
   PubMedGoogle Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S
   PubMed Web of Science ®Google Scholar
• Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol 2007;63:383-4
   PubMed Web of Science ®Google Scholar